Annals of Hematology

, Volume 91, Issue 4, pp 605–611 | Cite as

Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study

  • L. Kwofie
  • B. L. Rapoport
  • H. Fickl
  • P. W. A. Meyer
  • P. Rheeder
  • H. Hlope
  • R. AndersonEmail author
  • G. R. Tintinger
Original Article


The soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) is a useful marker of infection in patients with sepsis, but has not been adequately evaluated in patients with chemotherapy-associated febrile neutropenia (FN). The value of sTREM-1 in this setting has been tested in a retrospective, pilot study using stored serum from 48 cancer patients with documented FN. On presentation, patients were categorized according to the Talcott risk-index clinical score. Circulating soluble sTREM-1 was measured using an ELISA procedure, while procalcitonin (PCT) or interleukins 6 (IL-6) and 8 (IL-8), included for comparison, were measured using an immunoluminescence-based assay and Bio-Plex® suspension bead array system, respectively. Circulating concentrations of both sTREM-1 and PCT were significantly (P < 0.05) elevated in patients at high risk for complications or death, as predicted by the Talcott score and were significantly lower in patients who responded to empiric antimicrobial agents. Neither IL-6 nor IL-8 accurately predicted serious complications in patients with FN. These observations, albeit from a pilot study, demonstrate that sTREM-1 is indeed elevated in high-risk patients with FN and is potentially useful to predict their clinical course, either together with, or as an alternative to PCT.


Febrile neutropenia Soluble TREM-1 Talcott score Procalcitonin 

Supplementary material

277_2011_1339_MOESM1_ESM.pdf (34 kb)
ESM 1 (PDF 34 kb)


  1. 1.
    Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266PubMedCrossRefGoogle Scholar
  2. 2.
    Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Arch Int Med 148:2561–2568CrossRefGoogle Scholar
  3. 3.
    Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott JA (2000) The multinational association for supportive care in cancer risk-index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMedGoogle Scholar
  4. 4.
    Nakagawa Y, Suzuki K, Masaoka T (2009) Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15:174–179PubMedCrossRefGoogle Scholar
  5. 5.
    Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407PubMedCrossRefGoogle Scholar
  6. 6.
    Jimeno A, Garcia-Velasso A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muňoz A, López-Martin A, Durán I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100:2462–2469PubMedCrossRefGoogle Scholar
  7. 7.
    Uys A, Rapoport BL, Fickl H, Meyer PWA, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10. Eur J Cancer Care 16:475–483CrossRefGoogle Scholar
  8. 8.
    Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson L-O, Tidefelt U (2005) Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 74:297–303PubMedCrossRefGoogle Scholar
  9. 9.
    Massaro KSR, Costa SF, Leone C, Chamone DAF (2007) Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 7:137. doi: 10,1186/1471-2334-7-137 PubMedCrossRefGoogle Scholar
  10. 10.
    Prat C, Sancho JM, Dominguez J, Xicoy B, Giminez m, Ferra C, Blanco S, Lacoma A, Ribera JM, Aurina V (2008) Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 49:1752–1761PubMedCrossRefGoogle Scholar
  11. 11.
    Semeraro M, Thomée C, Rolland E, Le Deley MC, Rosselini D, Troalen F, Amoroso L, Drubel M, Hartmann O (2010) A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. Pediatr Blood Cancer 54:284–290PubMedGoogle Scholar
  12. 12.
    Schultz MJ, Determann RM (2008) PCT and sTREM-1: the markers of infection in critically-ill patients? Med Sci Monit 14:RA241–RA247PubMedGoogle Scholar
  13. 13.
    Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21:1–9CrossRefGoogle Scholar
  14. 14.
    Jiyong J, Tiancha H, Wei C, Huahao S (2009) Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive Care Med 35:587–595PubMedCrossRefGoogle Scholar
  15. 15.
    Tejera A, Santolaria F, Diez M-L, Alemán-Valls M-R, Gonzáles-Reimers E, Martínez-Riera A, Milena-Abril A (2007) Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 38:117–123PubMedCrossRefGoogle Scholar
  16. 16.
    Lin CH, Ho CC, Yao M, Hsu SC, Yu CJ (2009) sTREM-1 (soluble triggering receptor expressed on myeloid cells-1) as marker indicating infection in patients with neutropenic fever. Am J Respir Crit Care Med 179:A4704Google Scholar
  17. 17.
    Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer risk-index score. Support Care Cancer 12:555–560PubMedCrossRefGoogle Scholar
  18. 18.
    Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P et al (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicenter study. Clin Microbiol Infect 10:628–633PubMedCrossRefGoogle Scholar
  19. 19.
    Stryjewski GR, Nylen ES, Bell MJ et al (2005) Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med 6:129–135PubMedCrossRefGoogle Scholar
  20. 20.
    Porfyridis I, Plachouras D, Karagianni V, Kotanidou A, Papiris SA, Giamarellou H, Giamarellos-Bourboulis EJ (2010) Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect Dis 10:286–295PubMedCrossRefGoogle Scholar
  21. 21.
    Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic therapy for low risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMedGoogle Scholar
  22. 22.
    Lav RC, King SM, Richardson SE (1994) Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr Hematol Oncol 11:417–421CrossRefGoogle Scholar
  23. 23.
    Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia. A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMedGoogle Scholar
  24. 24.
    Han YY, Doughty LA, Kofos D, Sasser H, Carcillo JA (2003) Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med 4:21–25PubMedCrossRefGoogle Scholar
  25. 25.
    Sarmati L, Beltrame A, Dori L, Maffongelli G, Cudillo L, De Angelis G, Picardi A, Ottaviani L, Cefalo MG, Venditti A, Amadori S, Arcese W, Andreoni M (2010) Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. Am J Hematol 85(5):380–383PubMedGoogle Scholar
  26. 26.
    Kelso A (1998) Cytokines: principles and prospects. Immunol Cell Biol 76:300–317PubMedCrossRefGoogle Scholar
  27. 27.
    Yamamura M, Uyemura K, Deans RJ et al (1991) Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277–279PubMedCrossRefGoogle Scholar
  28. 28.
    Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J, Gaur AH (2010) Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 29:53–59PubMedCrossRefGoogle Scholar
  29. 29.
    Karapanagiotou EM, Pelekanou E, Charpidou A et al (2008) Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Anticancer Res 28:1411–1416PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • L. Kwofie
    • 1
  • B. L. Rapoport
    • 2
  • H. Fickl
    • 1
  • P. W. A. Meyer
    • 1
  • P. Rheeder
    • 3
  • H. Hlope
    • 2
  • R. Anderson
    • 1
    Email author
  • G. R. Tintinger
    • 3
  1. 1.Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health SciencesUniversity of Pretoria and Tshwane Academic Division of National Health laboratory ServicePretoriaSouth Africa
  2. 2.The Medical Oncology Centre of RosebankJohannesburgSouth Africa
  3. 3.Department of Internal Medicine, Faculty of Health SciencesUniversity of PretoriaPretoriaSouth Africa

Personalised recommendations